艾迪药业: 艾迪药业第三届监事会第四次会议决议公告

Meeting Overview - The third meeting of the Supervisory Board of Jiangsu Aidi Pharmaceutical Co., Ltd. was held on June 27, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the proposal to cancel part of the unvested restricted stock, stating that it complies with relevant laws and regulations, and does not harm shareholders' interests [1][2]. - The Supervisory Board approved the draft of the 2025 Stock Option Incentive Plan, which aligns with legal requirements and is expected to benefit the company's sustainable development [2][3]. - The Supervisory Board approved the implementation assessment management measures for the 2025 Stock Option Incentive Plan, ensuring smooth execution and alignment with the company's governance structure [3][4]. - The Supervisory Board verified the list of initial incentive objects for the 2025 Stock Option Incentive Plan, confirming their qualifications under relevant laws and regulations [4][5]. - The Supervisory Board approved changes to certain fundraising investment projects and amount adjustments, aimed at enhancing operational stability and profitability [5][6]. - The Supervisory Board agreed to nominate Tang Jieqing as a candidate for a non-employee representative supervisor, pending shareholder approval [6][7]. - The Supervisory Board elected current employee representative supervisor Pang Qiuchen as the chairman of the Supervisory Board, effective immediately [7].